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Abstract
Background: Mass drug administration (MDA) is a strategy widely used in the control of human parasitic diseases
but has been rarely attempted with malaria, the most common and dangerous parasitic disease in humans. MDA
is an intervention strategy that involves simultaneously dispensing treatment to an entire population in a given
geographic area. With some areas in sub-Saharan Africa documenting a decline in malaria transmission, the feasibility
of MDA to further reduce malaria transmission is being considered. Understanding community perceptions of such an
activity is vitally important for the design of the study and gaining the support of participants in order to maximize
compliance and adherence.
Methods: A qualitative study to assess factors likely to influence community acceptance of MDA in the seasonal and
low malaria transmission setting of The Gambia was conducted. Using in-depth interviews, the perceptions, knowledge
and attitudes of medical personnel and community members who have undergone MDA trials in The Gambia were
investigated.
Results: Several major themes emerged, namely: 1) the importance of timing of rounds of MDA doses for maximum
participation; 2) the need to educate the target population with accurate information on the procedures, drug
regimen, and possible side effects to enhance adherence; 3) the need for continuous sensitization meetings to
maintain and increase uptake of MDA; and, 4) the importance for defining roles in the delivery and assessment of
MDA, including existing healthcare structures.
Discussion: To increase the likelihood of participation in MDA trials in this setting, activities should be undertaken just
before and during the rainy season when community members are less mobile. Importantly, fears regarding blood
sampling and side effects of the drug regimen need to be addressed prior to the start of the trial and repeated
throughout the study period. Accurate and frequent communication is essential, and village leaders should consistently
be included in sensitization meetings to enhance community participation. Additionally, village healthcare workers
should be included in training and implementation, with supervision by a fieldworker permanently posted in every
few villages during the trial. Future collaboration with Senegal may prove important for enhanced elimination efforts in
The Gambia.
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Background
Malaria control and elimination
Of the areas of the world where malaria remains
endemic, approximately one-third of the countries are
pursuing strategies to transition from control to elimination
of the disease [1]. Transmitted by the female Anopheles
mosquito, malaria still infects approximately 200 million
people per year and accounts for 600,000 deaths annually
[2]. The majority of the disease burden afflicts sub-Saharan
Africa, where the most deadly of the parasites, Plasmodium
falciparum, is most prevalent. Recent findings note
that in low endemic countries and seasonal settings, a
large proportion of P. falciparum infections are carried
asymptomatically and in low densities, resulting in false
negatives using normal diagnostic tests such as blood slide
microscopy or malaria rapid diagnostic tests [3]. Treating
these asymptomatic infections is likely to have a greater
effect on malaria transmission than just treating
symptomatic patients who report to health facilities [4].
Elimination efforts
Mass drug administration (MDA) is the simultaneous
dispensing of treatment to an entire population in a specific
geographic area, regardless of presence or absence of dis-
ease symptoms and without diagnostic testing. MDA is the
control strategy of choice in other parasitic diseases, such
as lymphatic filariasis, schistosomiasis, and onchocerciasis
[5-7]. However, current studies of MDA for malaria have
shown mixed results, with some evidence of success yet no
long lasting effects in either sub-Saharan Africa or the Asia
Pacific [8-12].
Specific to malaria infection, there is emerging evidence
that MDA may be more effective when targeting both the
asexual and the sexual (gametocyte) stages of the parasite’s
lifecycle [4]. Although insufficient alone for malaria
elimination, destroying both the asexual stages and the
gametocytes in human hosts can have a significant
effect on reducing transmission if MDA is successfully
implemented before transmission season begins [13,14].
Such evidence has provided improvements to trial designs,
but evaluation of implementation methods is also needed
to more comprehensively improve MDA programmes.
Identifying barriers
One notable cause of MDA programme failures is the
lack of coverage of the target population and participant
adherence to the drug regimen [15]. It is estimated
through modelling that coverage of the target population
in excess of 80% is needed for MDA to be successful.
This assumes a static population and does not account
for humans migrating into the MDA area with new
infections [15].
Research indicates that misconceptions within MDA
target populations contribute to lack of initial compliance
and ongoing adherence to the drug regimen, and therefore
are barriers to success [16,17]. Specific misconceptions
attributed to those implementing MDA campaigns
include lack of trial justification to the community,
community misunderstanding of the medicine being
administered, who are at risk for the disease, and the
need to target asymptomatic carriers [18]. There are
limited reports focusing on how best to change MDA
campaigns to increase success within the community.
These studies do, however, suggest that a large part
of successful MDA implementation is due to community
education and health worker training [18,19].
Malaria mass drug administration in the Gambia
In 1999, an MDA for malaria was trialed in the seasonal
and low-transmission setting of the Gambia, and did
not yield a significant reduction in transmission [12].
In addition, a 2001 follow-up study exploring the
shortcomings of this malaria MDA trial had narrow
participant inclusion, which limited its ability to provide
useful information for improving future MDA trials [20].
Further understanding of the barriers to adherence and
community mobility has the possibility of enhancing the
effectiveness of MDA trials.
Importantly, investigations into the lack of adherence in
studies of MDA should involve a spectrum of stakeholders
and participants, such as health care workers, village
leaders, government officials and community members.
Therefore, this qualitative study was conducted to explore
the community barriers to MDA trials by exploring the
perceptions, knowledge and attitudes of participants in a
malaria MDA trial in The Gambia that took place in
1999. The goal of this study was to identify barriers and
facilitators to the MDA trial with the goal of increasing
adherence in future campaigns.
Methods
Study population and study sites
This study predominantly targeted individuals affiliated
with a malaria MDA trial from 1999 in The Gambia, but
also included several individuals involved in a 2010
trachoma MDA trial in The Gambia. Participants were
selected from various levels of involvement in the MDA
trials. This included researchers, fieldworkers, government
officials, and healthcare personnel. Additionally, the study
included village members from rural communities within
the North Bank Division of The Gambia who participated
in the 1999 malaria MDA trial.
Procedures
Participant recruitment was carried out through a mixed-
sampling approach, including both purposive and snowball
sampling techniques. Key informants were identified in
collaboration with the Medical Research Council Gambia
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Unit, the National Malaria Control Programme (NMCP),
the Centre for Innovation Against Malaria (CIAM), and
various major urban health facilities. Key informants
were contacted to participate via email or phone. Initial
participants were drawn from positions considered as
“stakeholders” in previous campaigns [12], such as the
researchers, project managers, fieldworkers and government
officials. Stakeholders were asked to both participate in the
interview and to refer individuals to participate in
the study. Likewise, village leaders of participating
districts were first approached, and asked to engage
in the interviews and then recruit members of their
community to participate. Only individuals who did
not wish to participate were excluded.
Data collection
A pre-piloted, semi-structured interview questionnaire was
used for data acquisition. The research constructs aimed to
address: 1) beliefs of key determinants to successful
MDA trials; 2) reasoning behind non-compliance and
non-adherence; 3) communication between acting parties;
and, 4) how the trachoma and malaria MDA trials
compared and contrasted. Interviews were audio-recorded
and transcribed at the end of each day with the assistance
of a fieldwork translator.
Data analysis
Interviews were transcribed using an inductive, iterative
process including: 1) familiarization with individuals,
questionnaire, and study area; 2) coding the data by
abstracting texts; 3) identifying themes and concepts; 4)
refining; and, 5) report writing. All analysis of interviews
was done by hand coding, and emerging themes were
identified based on frequency of appearance. Discrepancies
in coding were reviewed by a fieldwork assistant and
further reviewed by the fieldwork mentor when necessary.
Ethical considerations
The Medical Research Council The Gambia’s Institutional
Review Board and the University of California, San
Francisco’s Committee on Human Research approved
this study. A written informed consent form was read
and signed by all participants.
Results
Interviews were conducted with 26 key informants,
located in the towns of Fajara, Basse, and Farafenni,
and in the villages of Bambally, Kunjata, Sarakunda,
Pallen fulla, and Kanikunda Suba. Key informants
included a variety of stakeholders and community
members involved in the 1999 malaria MDA trial in
The Gambia, as well as several involved in a 2010
trachoma MDA in The Gambia (see Table 1 for key
informant abbreviations).
The following major themes were identified:
Theme 1 Participants emphasized that timing of
the mass drug administration was essential for a
successful campaign, but opinions differed on
whether administration during the dry or rainy
season would improve participation
Many village residents believed MDA campaigns should
occur during the dry season, due to farming obligations in
the rainy season.
The best time is during the dry season, because during
the rainy season everybody has gone to the farms.
(VHCW 3)
It should be in the dry season, because during the
rainy season people are busy.
(C 5)
It can be given during the dry season, because
I remember during the rainy season I took the
medication and felt dizzy and could not work.
(C 6)
Conversely, researchers and opinion leaders argued that
community members use their time off in the dry season
to travel, therefore participation would be maximized
during the rainy season.
The best time to do a trial is during the rain, from June
onwards. Because everyone sees themselves staying in
the village, in the community doing their fun activities,
they don’t move out. But during December, dry season,
people travel anywhere they like to. It is very difficult to
control them during the dry season.
Table 1 List of key informants by strata, involved in malaria
mass drug administration unless otherwise specified
Strata Abbreviation Number of key informants
Researchers R 3
Fieldworkers FW 2
Government officials GO 3
Village reporters VR 3
Village healthcare workers VHCW 3
Community members C 6
Opinion leaders OL 4
Trachoma researchers TR 2
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(R 3)
The medication should be given in the rainy season. The
only disadvantage with that is that if the medication is
if they feel dizzy they cannot work in the farms.
(OL 4)
I would prefer it in June because June is beginning
of rainy season in The Gambia. It is a month that
people are busy, but it is a month that is good for
such to happen.
(R 2)
Absence from the village during time of administration
was identified as an obstacle to MDA success. Travelling
outside of the village often extends across the border to
Senegal. Several government officials suggested that
Senegal be included in a future MDA trial.
At least 20% of your population floats. So I think that’s
the major problem—trying to catch people who aren’t
there and know that you haven’t caught them, even. I
think it’s a problem because in The Gambia it’s
surrounded so much by Senegal. The borders, of course,
are extremely porous as they should be—the countries
are at peace, people should be able to move around.
(R 1)
Because you know there’s cross-border contamination.
You will not be able to achieve real impact with MDA
without collaborating with Senegal.
(GO 3)
Theme 2 Adherence and compliance to the MDA
was dependent on participants’ understanding of
the procedures, drug regimen, possible side effects,
and eligibility for the trials
A concept frequently reported by fieldworkers and
villagers was the fear of blood samples being sold.
Villagers were familiar with newer methods of malaria
diagnostics that only require a finger prick for detection of
parasitemia, therefore skepticism increased with the
requirement of blood taken from the arm. Researchers
and fieldworkers reported an understanding of the need to
bleed participants from the arm, but villagers themselves
did not express this understanding.
They didn’t participate because of the blood people
were taking. They said eventually they came to believe
that they would sell the blood, they would sell our
blood. This led to a lot of refusals.
(VR 2)
Well sometimes bleeding is a problem to these people,
like frequent bleeding. Some people might think it will
only go for a few months and stop, so when it’s
continuing some people may change their minds.
(R 3)
The reason why some of them denied is because they
know with malaria, you can tell just by taking the
blood here [points to finger tip] but then they started
to take blood from here [points to arm] they said it
was too much to test for malaria.
(VR 2)
Fieldworkers and community members struggled
with compliance and adherence due to the dosage
including too many pills, particularly with the frequency
of administrations.
A participant who said ‘I want to take part, but these
drug that you are giving to us is too much’. It is seven
tabs, and he said ‘this is too much, I cannot swallow
all this’
(FW 1)
They just refused and said it was too many tablets
and they did not want to drink that many tablets.
(OL 4)
Villagers reported physical side effects of the medicine,
which reduced their adherence to the MDA drug
regimen. The side effects bothered them most during
the rainy season because it stalled their work in the
farms, therefore interfering with the daily provision to
their families.
We drank the medication, but when we went to the
bush to do the farming, we had to lay down and sleep
because it made us dizzy. It was not easy with our
stomachs.
(C 3)
When they drank the medication they get dizzy,
and when they go to the farms they cannot
do anything.
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(OL 1)
Some refusals were reported based on a state of
pregnancy or intention of pregnancy. Some women of
childbearing age chose to not take the medication for
this reason.
I feel that the reason most didn’t drink the medication
is because they told us if we are just a few months
pregnant we cannot take the medicine.
(C 4 and 5)
Theme 3 Sensitization sessions, the formal
educational meetings that occur between
researchers and study population, were reported as
the most important component of an MDA trial
Key informants consistently reported that the most
important element of a mass drug administration is the
sensitization of the community to the study and the
procedures.
It is sensitization, it has to be very clear to them and it
has to be before the study starts. If there is any
procedures, blood taken, whatever amount, you have
to make sure that during the sensitization everything
is solved.
(R 2)
I believe if there is proper sensitization, people will
understand.
(OL 2)
I didn’t have enough time to disseminate the
information to the villages. Because prior to the start
of the trial we said we wanted to go around to the
villages, but it did not materialize.
(FW 2)
Researchers and opinion leaders reported the influence
of village members who often diagnose and treat dis-
eases without a legitimate healthcare certification. Key
informants recognized that these people may distort the
trial results in some way, and sensitization efforts spe-
cific to them should be made.
Sometimes you have the shopkeepers giving the drugs,
the antimalarial drugs.
(R 3)
Sensitization should be very wide and extend to the
shopkeepers, drug sellers, and whatever else in the
community, so they do not interfere with the study.
(OL 3)
A new element of the sensitization campaigns that was
suggested consistently across key informants was use of the
media. Particularly in comparing the trachoma and malaria
MDA trials of The Gambia, it became apparent that the
media was not used in the 1999 malaria MDA campaign.
Sensitization, we used various media for that, what
with the electronic and billboard structures.
(TR 1)
It starts with various education channels to
communicate with the community. They use the media,
like radio for example. They develop a message in the
various languages and they use those to relate. The
radio is not available to all, but it is available to many.
(GO 1)
We had two radio stations before the distribution,
where we sensitized the individual villages and tell
them the effect of trachoma. And we allow phone calls
even, to call in with any of their questions and we
answer it. So it was effective.
(TR 2)
Over time, the attitude toward intervention trials in
the rural communities has transitioned from skeptical to
more accepting.
If you can look at the time that the MDA was done,
there was not a lot of awareness. There is more
awareness now, and those who are part of the
programme are much stronger now so they can
convince those people who are not ready to be part of
the programme.
(C 1)
I know things are changing from 1999 to now, because
now people are conferring consent to research in The
Gambia because sensitization is an ongoing thing.
(OL 3)
Initially, there was no awareness. But since the
campaign started there was awareness, people were
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sensitized, and people became to know the importance
of the project.
(VHCW 2)
Sensitization sessions themselves should be based on
community preferences.
Involve us; we should be the example.
(C 6)
Normally we don’t suggest, we go to the community
and ask what day would be best for them.
(R 2)
This is why fieldworkers have their own time to visit
their study subjects: what time is convenient? As you
stay with them in the community, you will know what
time is convenient. It all depends on how you’re going
to plan your work according to their schedules
(R 3)
Theme 4 Those involved in MDA trials need defined
roles and improved cohesion. Existing healthcare
structures must be taken advantage of to maximize
efficiency and effectiveness of information
dissemination, compliance, and adherence
Villagers, fieldworkers, and researchers emphasized the
need for improved communication between and among
themselves.
It should be communication between the ones that are
the researchers–the people who are bringing this type
of programme into the community–and the community
leaders.
(VR 3)
Such a programme needs a lot of dialogue between the
people and the person disseminating the information
and the person implementing the programme. You need
to know the community very well—you need to know
which individuals are barriers to the campaign, and be
able to approach them before the project begins.
(FW 2)
Communication between all participants must be truthful,
consistent and frequent. This includes an initiative on all
parts to identify and absolve barriers to trials.
You have to be sure your staff is telling you really what’s
happening, because you can’t go to everyone yourself.
(R 1)
I feel there is no good interpreter between the doctors
and the local community. And sometimes this delays
jobs being done.
(OL 2)
There is not a consensus amongst key informants
whether the results of the 1999 MDA were reported back
to the target populations.
No we did not go to them to tell them the programme
had failed. They should know, they need to know so at
the end of the day we will be free from blame.
(FW 2)
In regards to the trial– I was a part of it, but after-
wards there was no feedback for me. I believe this is
something that is lacking from my own point of view;
giving feedback to the community, it’s not done.
(R 2)
Several key informants suggested a fieldworker, closely
related to the researchers conducting the trial, be
permanently posted in every village, or every few villages.
There needs to be a type of person that can be relied
upon by the general community for questions.
(VR 1)
Some of them come before even and start asking
questions. Because even out of working hours, some
people can be passing by and come into my house and
say ‘I have a doubt’.
(FW 1)
According to many key informants, local staff must be
used more effectively. Although this will require additional
training efforts, it is reported that involving village health
care workers and local staff will engage communities more
quickly and effectively.
I recommend that if you want to do this kind of thing,
you link with the primary health care worker in the
village. If you link with that man, you have a lot of
influence over the people.
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(VR 2)
If they are taking from our practice, they should be
taking the existing structures from the community.
And that’s what we did; we used the existing structures
with emphasis on training.
(TR 1)
Opportunities to recruit traditional healers should be
taken advantage of. Key informants from the trachoma
MDA trials explained participation of village health
workers called Nyaterros, or ‘friends of the eye’. These
individuals proved important for advocacy, dissemination
of information and signifying trust between the target
communities and research personnel.
So you go in and you have Village Health Workers, or
another group called Nyaterros. Nyaterros is a
Mandinka word referring to ‘friends of the eye’. The
staff was local staff that the people already know. So
during the campaign these are the same team
members that lead the team.
(TR 1)
The districts whereby we treated everybody, we used
the ophthalmic nurses, we used the scouts, the
reporters, students from the schools. So those are the
people we use during the treatment, during the
distribution, because the job was very hectic.
(TR 2)
Discussion
This qualitative study in The Gambia examined community
barriers to malaria MDA trials by interviewing stakeholders
and community members involved in a 1999 malaria study
and a 2010 trachoma study.
First, interviews with community members revealed a
preference for MDA during the dry season due to their
farming obligations during the rainy season. Although
a valid preference, this finding was contradicted by
researchers and opinion leaders interviewed who felt
that participation in the dry season would always be
limited because of ceremonies and freedom to travel.
The potential for maximal participation would be
greater during the rain because of farming duties, but
working demands and side effects of the medicine
may be legitimate reasons to avoid MDA during this
period. Soliciting preferences from the community in
initial sensitization meetings could help solve this
challenge, which is further explored in Theme 4, revolved
around communication. Substantial evidence is lacking as
to which season may be superior to employ MDA.
However, MDA implemented just before or during
the rainy season in The Gambia may have a significant
impact given the highly seasonal nature of transmission in
this area [21]. Several government officials suggested
collaboration with Senegal, arguing the potential for
increased participation through broad-scale implementation
that caters to the natural movement to and from different
communities.
Second, major barriers to compliance and adherence of
MDA trials are a product of participants’ perceptions of
the procedures, drug regimen, possible side effects, and
eligibility for the trials. Although participation may
initially be high, misconceptions and miscommunications
typically arise over time and result in decreased participa-
tion. Villagers expressed a fear of blood sampling for
malaria parasite detection, as it was drawn intravenously
in the 1999 MDA trial. Given that malaria testing is
currently done by rapid diagnostic test or microscopy in
this setting (requiring only a finger prick blood sample),
this fear is understandable and could be resolved by
informing participants prior to the beginning of MDA that
updated diagnostic methods no longer require intravenous
blood samples. Further, villagers cited difficulty with the
drug regimen due to the number of pills required. Explicit
explanations of ACT dosage and possibility of side effects,
with physical examples of tablet size and number, should
be included in sensitization sessions. The number of
pills and tablet size may vary across different ACT
combinations, and the quantity of pills has been reported
to deter compliance in sub-Saharan Africa [22]. Similar
problems have been found in lymphatic filariasis
MDA trials, with non-compliance resulting from fear
of side-effects despite drugs being well-tolerated by
participants [23,24].
Third, sensitization sessions were conveyed as the
most essential component of a successful MDA trial. Not
only do they provide overall information and allow
community members to ask questions but, importantly,
sensitization sessions also address cultural courtesies and
establish a relationship between study populations and
research staff. Although community acceptance of MDA
trials has increased over the last few decades according to
this study’s findings, sensitization still needs refining to
ensure consistent and clear information is disseminated
to study populations. For example, the attendance of
key personnel, such as the Alkalo (village leaders),
Imam (religious leader), and other leaders of groups
(youth or women) may play an important role in
community buy-in given their status as decision makers
and leaders [25]. Additionally, identifying others in
the area who may be diagnosing and treating malaria
(such as private pharmacy workers) is important for
comprehensive coverage. Such individuals may not be
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apparent to the organizers of MDA trials, but can be
identified and included in sensitization sessions with
the help of village leaders. Sensitization sessions should
also be arranged well in advance of the MDA trial, as well
as immediately before, during, and after it has commenced.
Media were not used as a promotional tool in the 1999
malaria MDA trial in The Gambia, but were a successful
component of the trachoma campaign’s strategy according
to key informants. Radio, television and billboards were
important avenues for information dissemination and
timing reminders, and increased the likelihood of reaching
each community member. Information should be
dispersed using a mixed-method approach, relying
mainly on sensitization meetings with individual villages
and supplemented by reminders and promotions through
media. Villagers should be included during the planning
of sensitization sessions to offer suggestions on how they
should be run and who should be present.
Lastly, as with any top-down intervention, partici-
pants must communicate and collaborate cohesively.
Communication was identified as the biggest challenge to
an MDA trial, specifically the gap between fieldworkers
(the individuals assisting researchers) and the villagers. This
flow can be characterized bi-directionally, by information
disseminated from fieldworkers to the community or by
concerns articulated from the community to the fieldworkers
and up to the research personnel. Lack of efficient
and effective communication to villagers is likely due
to inadequate fieldworker training. It is important
that the fieldworker be able to articulate the future
benefits and implications of the MDA trial, and to do so
regularly given the constant testing and administering of
drugs throughout the trial. Importantly, the information
disseminated in either direction should be truthful,
consistent and frequent, aiming to identify and resolve
barriers to trials. Further, information should continue to
be disseminated back to the communities even after the
MDA trial has stopped. This will help foster the trust
established between rural populations and the research
community, and will help justify the villagers’ investment
in the trial.
As accuracy and consistency of information were
repeatedly reported as essential elements of sensitization,
key informants also gave suggestions on how to best
restructure an MDA to address this. Questions and con-
cerns from villagers are apparent from the beginning of
sensitization through the end of any such intervention.
Therefore, consistent and readily available information is
essential. A possible solution to several adherence issues
could involve permanently posting a fieldworker in each
participating village. Several fieldworkers and trachoma
researchers relayed that there needs to be a person in the
village that can be constantly relied upon by the general
community for questions regarding the trial. This also
might be an opportunity to take advantage of local
health staff, like community health care workers, who
would convey information to a supervising fieldworker.
Additional training sessions would be required if including
local health staff in an MDA trial. However, this training
might be coupled with fieldworker training and therefore
potentially alleviate barriers to community education and
participation efforts. Involving traditional healers in MDA
trials may also be important to demonstrate advocacy and
enhance community participation [26]. Traditional healers
are revered in rural communities in The Gambia, making
them an important group to involve in sensitization
sessions and the actual drug administration days [27].
It has been seen in other disease-specific interventions in
The Gambia that advocacy and assistance from village
healthcare workers can increase compliance and sustainabil-
ity [28,29]. Therefore, future trials in The Gambia should
specifically target village healthcare workers, include
them in training, and solicit their help in information
dissemination and during administrations.
Limitations
This study has two distinct limitations, the first being
that interviews may include biased views due to the
inherent nature of snowball and purposive sampling.
However, this limitation was recognized prior to sampling
and the diversity of participants aimed to even out any
possible bias. Secondly, information collected in this study
is not only specific to The Gambia, but also specific to
MDA trials for malaria. Therefore, results are likely not
transferable to other settings, but may still be used to
inform other MDA trials.
Conclusions
Participation in malaria MDA trials may be maximized
during the rainy season, when all villagers are working
in the farms. However, villagers prefer not to have drugs
administered during this time, so targeting the transition
window between the rainy and dry seasons may be a
successful compromise. Fears around blood sampling
and medications given during the MDA trial should be
addressed during sensitization meetings in advance of
the actual trial administration. Importantly, accurate and
frequent communication is essential, both to and from
target populations. The use of local media as an adjunct
to sensitization sessions may increase uptake within the
community. In further malaria MDA trials, including a
designated, trained fieldworker in each village during
trial administration may increase compliance and reduce
fears for participating residents.
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